Chronic myelomonocytic leukemia (CMML) is a complex clonal hematological disorder classified among myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). Prognosis is poor and there is a lack of effective treatments. The hypomethylating agent decitabine has shown activity against MDS and elderly acute myeloid leukemia, but there is little data focusing specifically on its efficacy in CMML. In this prospective, phase 2 Italian study, CMML patients received i.v. decitabine 20 mg/m(2)/day on Days 1 to 5 of a 28-day treatment cycle. Response was evaluated after 4 and 6 cycles; patients responding at the end of 6 cycles could continue treatment with decitabine. Forty-three patents were enrolled; >50% were high-risk according to four CMML-specific scoring systems. In the intent-to-treat population (n=42), the overall response rate after 6 cycles was 47.6%, with 7 complete responses (16.6%), 8 marrow responses (19%), 1 partial response (2.4%) and 4 hematological improvements (9.5%). After a median follow-up of 51.5 months (range: 44.4-57.2), median overall survival was 17 months, with responders having a significantly longer survival than non-responders (P=0.02). Grade 3/4 anemia, neutropenia and thrombocytopenia occurred in 28.6, 50 and 38% of patients, respectively. Decitabine appears to be an effective and well tolerated treatment for patients with high-risk CMML.Leukemia accepted article preview online, 13 June 2017. doi:10.1038/leu.2017.186.
Pharmacology, Toxicology and Pharmaceutical Science
1
2%
Physics and Astronomy
1
2%
Other
1
2%
Unknown
18
32%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 November 2020.
All research outputs
#2,674,178
of 29,868,835 outputs
Outputs from Leukemia
#682
of 6,253 outputs
Outputs of similar age
#39,597
of 339,919 outputs
Outputs of similar age from Leukemia
#19
of 97 outputs
Altmetric has tracked 29,868,835 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,253 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,919 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.
